The Case for Halozyme

The Setup

First, a word of credit. Halozyme came to our attention through Vibe, an independent biotech writer who laid out the bull case in his own detailed writeup and made the case for it as a growth-at-a-reasonable-price story. What follows is our own independent analysis, built from the platform data, the filings, and the patent record, but the credit for surfacing a company the broader market still overlooks belongs to him.

When a patient receives an antibody drug like Roche's Herceptin or Johnson & Johnson's Darzalex, the traditional route is an intravenous infusion: a needle in the arm, an hour or more in a chair, a nurse monitoring the drip. There is a better way. Mix the same drug with a particular enzyme and it can be injected under the skin in a few minutes. That enzyme, recombinant human hyaluronidase, is the product of one company. Halozyme spent more than two decades perfecting it, and today it sits inside the subcutaneous versions of some of the largest biologics on earth.

Halozyme does not run the trials, build the brands, or carry the commercial risk of those drugs. Its partners do. Halozyme licenses the enabling technology, called ENHANZE, and in return collects royalties, milestone payments, and manufacturing revenue. It is a toll booth. The cars belong to Roche, Johnson & Johnson, argenx, and Bristol Myers Squibb. The road is the multibillion-dollar shift from infusion to injection. Halozyme owns the booth.

This article is not going to argue that the stock is secretly cheap. It is not. After a strong year the shares trade close to the Wealth Engine Pro platform's calculated fair value, and we will be transparent about that. The argument is different and, the analysis suggests, more durable: this is a high-margin, fast-growing royalty business attached to a structural megatrend, available at a fair price, with optionality the backward-looking models do not capture. It also carries two real risks, a patent fight and a customer concentration, that deserve honest treatment rather than a footnote.

The Toll Booth Model

The economics of a royalty business are what make Halozyme unusual. When a partner sells an ENHANZE-enabled drug, Halozyme earns a percentage of that revenue without bearing the cost of the sales force, the clinical program, or the marketing. The incremental margin on a royalty dollar is close to total. That is why the company posts a return on equity near 99% and a return on invested capital above 28%: it is monetizing other companies' blockbusters with very little capital of its own.

The partner list reads like a tour of oncology and immunology. Johnson & Johnson's Darzalex FASPRO, the subcutaneous form of its multiple myeloma franchise, is the single largest contributor. argenx's VYVGART Hytrulo for autoimmune disease has become a fast-growing second engine. Roche markets subcutaneous Phesgo and Tecentriq, Bristol Myers Squibb sells Opdivo Qvantig, and Johnson & Johnson added a subcutaneous version of its lung-cancer drug Rybrevant. Each launch widens the base of products throwing off royalties, and royalties from an approved, selling drug tend to be sticky and recurring rather than one-time.

In the first quarter of 2026, royalty revenue reached $241 million, up 43% year over year, and total revenue rose 42% to $377 million. The growth is not coming from a single drug having a good quarter. It is coming from a portfolio of partner products that are individually large and collectively broadening, which is exactly the profile a royalty holder wants to see.

The Megatrend

A royalty business is only as good as the volume crossing the toll booth, and here the direction of travel is structural. The pharmaceutical industry is systematically converting its highest-value intravenous biologics into subcutaneous versions, and it is doing so for reasons that compound. Patients prefer a few minutes to a few hours. Health systems free up infusion chairs and nursing time. And manufacturers gain a way to defend a franchise as it ages, because a more convenient subcutaneous formulation can hold patients that a biosimilar of the old intravenous version would otherwise take.

The scale of that shift is large. Industry projections put the subcutaneous biologics market on a path from roughly $60 billion to more than $230 billion over the next decade. Clinical data keeps validating the move: studies of subcutaneous formulations have shown comparable and in some cases superior outcomes to the intravenous originals, which removes the last clinical objection to switching. Halozyme is not betting that one drug succeeds. It is positioned so that as the industry reformats its biggest franchises, a growing share of those reformatted products runs through its enabling technology. That is the difference between a product story and a platform story.

The Financials

The growth is translating into cash and into shareholder returns. Alongside its first-quarter results, Halozyme reaffirmed its 2026 through 2028 guidance and authorized a new $1 billion share repurchase program, with a commitment to buy back at least $400 million of stock in 2026 alone. The share count has already fallen by roughly 4.6% over the past year. For a company with a market value near $8 billion, a buyback of that size meaningfully shrinks the share base.

The balance sheet is the part of the financial story that requires attention rather than applause. Halozyme used debt, including convertibles, to fund acquisitions that built out its technology, and that leverage is elevated for a company of its size. The offset is the cash generation: the royalty model throws off enough free cash flow that management has guided toward bringing net leverage down to roughly 1.2 times by the end of 2026. Deleveraging on that timeline turns a current weakness into a future tailwind, but it depends on royalty growth continuing, which is why the risks later in this article matter.

The Next Royalty Engine

The bear concern about any royalty company is that its existing products eventually mature and the stream flattens. Halozyme's answer is a second technology platform. Through acquisitions it added high-concentration formulation capabilities, marketed under the Hypercon banner, that let partners pack more drug into a smaller subcutaneous injection. This matters because it extends the company's relevance beyond the original ENHANZE enzyme and, importantly, carries fresh intellectual property with a patent runway reaching into the 2040s, well beyond the horizon of the first-generation deals.

The pipeline behind the reported numbers is also deep. Halozyme has pointed to more than a dozen additional ENHANZE-enabled products in partner development, each a potential future royalty line that does not yet appear in revenue. The combination of a second formulation platform and a long bench of in-development products is what separates a durable compounder from a business quietly running down a fixed set of royalties. It is also the part of the story the systematic scoring cannot yet see, because none of it has reached a filing as revenue.

What the Wealth Engine Scores Say

Before we get to the valuation argument, here is what the Wealth Engine Pro platform's systematic scoring shows for this stock right now. In this case the scores carry an important message that complicates the bull thesis, and we are going to state it plainly.

A Company Strength of 69 places Halozyme firmly in the Strong tier, with solid Financial Health of 75, a Moat score of 11 of 15, and a Bullish outlook. But the Fair Value reading is the one to sit with: the platform calculates fair value at $71.96, which is essentially where the stock already trades. Unlike a classic Wealth Engine thesis built on a wide discount to fair value, this one offers almost no margin of safety on the platform's backward-looking math.

These scores are systematic. They evaluate companies based on reported financials, balance sheet quality, moat characteristics, and valuation models (DCF, peer comparison, earnings power). They measure what a company is today, not what it might become. That is by design: the scoring system is built to keep emotion and forward speculation out of the numbers.

This article is making a forward-looking argument: that the IV-to-subcutaneous megatrend, the deep pipeline of unlaunched ENHANZE products, and the Hypercon platform will keep royalties compounding well past what a model can credit before the revenue appears in filings. The scoring system has no way to price those in today. That is also why Wall Street price targets, which range from roughly $82 to $95 with a Buy consensus, sit above the platform's fair value: the analysts are crediting the forward ramp the systematic model holds back on.

Both perspectives are real data. The platform tells you the stock is fairly valued on what it has already proven. The article argues the forward setup justifies paying that fair price for a business growing royalties in the forties. Transparent investors use both. Research the stock yourself on the platform and decide which signal matters more for your situation.

The Valuation Case

At a share price in the high $60s and an enterprise value near $10 billion, Halozyme trades at roughly 10 times EV to EBITDA and about 15 times EV to free cash flow. For a business compounding revenue in the low forties percent, those are not demanding multiples. This is the textbook definition of growth at a reasonable price: you are not getting a fire-sale discount, but you are paying a fair, even modest, price for a genuinely fast-growing, capital-light franchise.

The reason the multiple stays grounded rather than expanding is that the market is discounting two things, both addressed in the next section: the patent dispute over the company's newer MDASE technology, and the concentration of today's royalties in a single franchise. The bull case does not require those risks to disappear. It requires the core royalty engine to keep growing while they play out, and the platform's own Bullish outlook, the reaffirmed multiyear guidance, and the Street's $82 to $95 targets all point to that being the base case rather than the hopeful one.

What Could Go Wrong

The first risk is concentration. Darzalex FASPRO, Johnson & Johnson's subcutaneous myeloma drug, accounts for more than half of Halozyme's royalty revenue, roughly $129 million of the $241 million booked last quarter. The composition-of-matter patents on the underlying antibody have already begun expiring, and while the subcutaneous co-formulation enjoys protection that Halozyme expects to support royalties into around 2030, biosimilar competition and pricing pressure on the franchise are the single largest vulnerability in the model. Anything that erodes Darzalex faster than the newer products ramp would hit the stream where it is most concentrated.

The second risk is the patent fight, and it has been going against Halozyme. Its MDASE technology, a separate and newer body of intellectual property from ENHANZE, is meant to let the company sign partners and extract licensing from rivals who use competing hyaluronidase enzymes. Merck challenged that portfolio aggressively, and on May 12, 2026 the U.S. Patent Trial and Appeal Board invalidated one of the core MDASE patents on the grounds that its claims reached beyond what the company had actually demonstrated. More than a dozen additional challenges are instituted and working through the system, so the headline risk is ongoing rather than resolved. The crucial distinction for the thesis: MDASE is not ENHANZE. The existing royalty streams from approved ENHANZE products are not affected by these rulings. What is impaired is the pricing power and licensing upside on future deals, including the prize of forcing a settlement with Merck over subcutaneous Keytruda. That optionality is now genuinely in doubt.

The third risk is competition at the platform level. Alteogen, a South Korean company, has developed a rival hyaluronidase that Merck, AstraZeneca, and Daiichi Sankyo have adopted, which is the very dispute at the heart of the MDASE litigation. Newer hyaluronidase-free delivery approaches are also in development. None of these displaces Halozyme's installed base of approved products, but they mean the company no longer has the field to itself for the next generation of deals, and that is precisely what the patent losses make harder to defend.

Finally, the balance sheet leverage discussed earlier is a real constraint if growth stumbles. The deleveraging path assumes royalties keep climbing. If Darzalex erodes early or a major partner launch disappoints, the debt becomes less comfortable at the same moment the growth narrative weakens. The platform rates Halozyme Bullish today, but a thesis that pays full fair value leaves little room for these risks to surprise to the downside, and that is the honest tradeoff a buyer accepts here.

The Thesis

Halozyme is a Strong, Bullish-rated royalty company that owns the enabling technology behind the subcutaneous versions of some of the largest biologics in the world, growing royalties 43% last quarter, returning capital through a fresh $1 billion buyback, and riding a structural shift from infusion to injection that is measured in the hundreds of billions of dollars. The contested intellectual property, the MDASE patents, is the optionality layer, not the engine. The cash engine, the existing ENHANZE royalties, is intact and compounding.

The thesis is deliberately not that this is a hidden bargain. The platform calls it fairly valued, and that reading is correct on the numbers the company has already reported. The argument is that a fair price is a reasonable price to pay for a capital-light compounder attached to a decade-long megatrend, with a second technology platform and a deep pipeline of unlaunched products that the backward-looking models cannot yet credit. That is growth at a reasonable price, and it comes with a patent fight and a concentration risk laid out in full rather than buried.

This is how the Wealth Engine Pro philosophy is meant to work. The platform does not inflate a number to fit a story; it scored Halozyme as Strong and fairly valued, and we reported that without softening it. The editorial case is that the forward setup, the royalty growth, the megatrend, and the optionality, justifies the fair price the market is asking, while the risks are real enough to keep the position honest. The data and the analysis point the same direction. They just do not promise a discount, and saying so is the point.